Clinical trial
A Study of the Drug Casopitant for the Prevention of Nausea Caused By…
NCT00431236 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00431236 |
|---|---|
| Title | A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy |
| Official title | A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, Administered in Combination With ZOFRAN and Dexamethasone for Prevention of… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Nausea and Vomiting, Chemotherapy-Induced |
| Intervention type | Drug |
| Interventions | Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride, Oral dexamethasone |
| Enrollment | 810 |
| Start date | Nov 6, 2006 |
| Primary completion | Oct 9, 2007 |
| Completion | Oct 9, 2007 |
| First posted | Feb 5, 2007 |
| Last update posted | Aug 22, 2017 |
| Countries | Argentina, Belgium, Bulgaria, Croatia, Czechia, Finland, Greece, Hungary, India, Ireland, Italy, Malaysia and 10 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: